このエントリーをはてなブックマークに追加
ID 47053
本文ファイル
著者
Kamikawa, Rintaro
Ikawa, Kazuro 大学院医歯薬保健学研究科(薬) 広大研究者総覧
Morikawa, Norifumi 大学院医歯薬保健学研究科(薬) 広大研究者総覧
Asaoku, Hideki
Iwato, Koji
Sasaki, Ayako
キーワード
thalidomide
pharmacokinetics
multiple myeloma
NDC
医学
抄録(英)
Thalidomide has been used for the treatment of refractory multiple myeloma, the dosage in Japan is lower than in other countries; however, there is little information on the pharmacokinetics and their relationship with the drug response. The aim of this study was to characterize the pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma, and to examine the relationship between pharmacokinetics and adverse events. On the first and second days, a 100 mg capsule was administered to 8 Japanese patients after breakfast and blood samples were obtained. The plasma concentrations were measured using HPLC and analyzed based on a one-compartment model. If intolerable adverse events were not observed for 14 d, the dose was increased to 200 mg. The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration–time curve from 0 to infinity (AUC0—∞), which were 45.3 l, 5.5 l/h and 21.7 μg·h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0—∞ than in Caucasian populations. This pharmacokinetic difference may explain the dose difference between Japan and other countries. Adverse events were associated with AUC0—∞, which was best correlated with plasma concentration at 12 h after administration. The 12-h time point was suggested to be a capable indicator for “safety-oriented” therapeutic drug monitoring of thalidomide.
掲載誌名
Biological and Pharmaceutical Bulletin
29巻
11号
開始ページ
2331
終了ページ
2334
出版年月日
2006-11
出版者
The Pharmaceutical Society of Japan
ISSN
0918-6158
1347-5215
NCID
出版者DOI
言語
英語
NII資源タイプ
学術雑誌論文
広大資料タイプ
学術雑誌論文
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
権利情報
© 2006 Pharmaceutical Society of Japan
関連情報URL
部局名
医歯薬保健学研究科